E-6123 |
| カタログ番号GC35922 |
E-6123は血小板活性化因子（PAF）受容体拮抗薬です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 131614-02-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
E-?6123 is a platelet-activating factor (PAF) receptor antagonist. PAF[1]
E-6123 (E6123) partially inhibits the Thapsigargin-induced increase in the levels of interleukin-6 mRNA and interleukin-6 protein. To clarify the role of the concurrently produced cell-associated PAF in the thapsigargin-induced increase in the interleukin-6 mRNA level and interleukin-6 production, the effects of the PAF receptor antagonist E-6123 are examined. E-6123 at 1 and 10 μM partially inhibits the Thapsigargin (46.1 nM)-induced increase in the interleukin-6 mRNA level at 4 h and interleukin-6 production at 8 h[1].
[1]. Ichinowatari G, et al. Participation of prostaglandin E2 and platelet-activating factor in thapsigargin-induced production of interleukin-6. Eur J Pharmacol. 2002 Jan 11;434(3):187-96.
| Cas No. | 131614-02-3 | SDF | |
| Canonical SMILES | O=C(C1CC1)N2CC3=C(CC2)C(C(C4=CC=CC=C4Cl)=N[C@H]5C)=C(S3)N6C5=NN=C6C | ||
| Formula | C23H22ClN5OS | M.Wt | 451.97 |
| 溶解度 | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2125 mL | 11.0627 mL | 22.1254 mL |
| 5 mM | 0.4425 mL | 2.2125 mL | 4.4251 mL |
| 10 mM | 0.2213 mL | 1.1063 mL | 2.2125 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *